Get help now — free helplines

You can call any of these for free. You do not need a diagnosis, an appointment, or a crisis to call — questions and plain exhaustion are reasons enough.

  • Alzheimer's Association 24/7 Helpline 800-272-3900 24 hours a day, 365 days a year Free, confidential support and information for people with dementia, caregivers, families and the public. Master's-level clinicians. Also Spanish.
  • 988 Suicide & Crisis Lifeline 988 24/7 Call or text 988, or chat at 988lifeline.org. For anyone in emotional distress or a mental-health crisis, including caregivers.
  • Alzheimer's Foundation of America (AFA) Helpline 866-232-8484 9:00 am - 9:00 pm ET, seven days a week Licensed social workers providing support, info and referrals. Also text message and web chat. Text: 646-586-5283

In a medical emergency, call 911. More numbers, and what each line does, on the help page.

This page is alzhub.org's plain-English summary of a published study, not the paper itself. It is generated from the record we hold for this study, sourced and linked below — check the original for the full text and methods.

✓ Peer-reviewed alzhub usefulness score 76 out of 100. Mild cognitive impairment

Topic: Amyloid, tau and blood-test diagnosis

Plain-language summary

A major unanswered question in the dementia field is whether cognitively unimpaired individuals who harbor both Alzheimer's disease neuropathological hallmarks (that is, amyloid-β plaques and tau neurofibrillary tangles) can preserve their cognition over time or are destined to decline. In this large multicenter amyloid and tau positron emission tomography (PET) study (n = 1,325), we examined the risk for future progression to mild cognitive impairment and the rate of cognitive decline over time among cognitively unimpaired individuals who were amyloid PET-positive (A + ) and tau PET-positive (T + ) in the medial temporal lobe (A + T MTL + ) and/or in the temporal neocortex (A + T NEO-T + ) and compared them with A + T - and A - T - groups. Cox proportional-hazards models showed a substantially increased risk for progression to mild cognitive impairment in the A + T NEO-T + (hazard ratio (HR) = 19.2, 95% confidence interval (CI) = 10.9-33.7), A + T MTL + (HR = 14.6, 95% CI = 8.1-26.4) and A + T - (HR = 2.4, 95% CI = 1.4-4.3) groups versus the A - T - (reference) group. Both A + T MTL + (HR = 6.0, 95% CI = 3.4-10.6) and A + T NEO-T + (HR = 7.9, 95% CI = 4.7-13.5) groups also showed faster clinical progression to mild cognitive impairment than the A + T - group. Linear mixed-effect models indicated that the A + T NEO-T + (β = -0.056 ± 0.005, T = -11.55, P + T MTL + (β = -0.024 ± 0.005, T = -4.72, P + T - (β = -0.008 ± 0.002, T = -3.46, P - T - (reference) group (all P + T NEO-T + (P + T MTL + (P = 0.002) groups also progressed faster than the A + T - group. In summary, evidence of advanced Alzheimer's disease pathological changes provided by a combination of abnormal amyloid and tau PET examinations is strongly associated with short-term (that is, 3-5 years) cognitive decline in cognitively unimpaired individuals and is therefore of high clinical relevance.

What this study adds

Evidence grade: Low

The record lists 1,325 participants. In this large multicenter PET study, cognitively unimpaired people who were positive for both amyloid and tau had a substantially increased risk of progressing to mild cognitive impairment compared with those negative for both. Reported effect size: HR = 14.6; HR = 2.4; HR = 6.0.

Taken from this record’s own fields, not from reading the paper. The grade is assigned from the abstract’s wording; what that means.

Cite this study APA, Vancouver, BibTeX · download .bib or .ris

APA 7th

Ossenkoppele, R., Pichet Binette, A., Groot, C., Smith, R., Strandberg, O., Palmqvist, S., et al. (2022). Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature medicine. https://doi.org/10.1038/s41591-022-02049-x

Vancouver

Ossenkoppele R, Pichet Binette A, Groot C, Smith R, Strandberg O, Palmqvist S, et al. Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline. Nature medicine. 2022. doi:10.1038/s41591-022-02049-x. PMID: 36357681.

BibTeX

@article{ossenkoppele2022-36357681,
  author  = {Ossenkoppele, R. and Pichet Binette, A. and Groot, C. and Smith, R. and Strandberg, O. and Palmqvist, S. and Stomrud, E. and Tideman, P. and others},
  title   = {{Amyloid and tau PET-positive cognitively unimpaired individuals are at high risk for future cognitive decline}},
  journal = {Nature medicine},
  year    = {2022},
  doi     = {10.1038/s41591-022-02049-x},
  pmid    = {36357681},
  url     = {https://doi.org/10.1038/s41591-022-02049-x}
}

Built from the record alzhub holds for this paper, not looked up. Volume, issue and page numbers are not held in the record. The record's author list ends in “et al.”, so not every author is named. Check the citation against the original before you use it.

Key findings

Why it matters

In this large multicenter PET study, cognitively unimpaired people who were positive for both amyloid and tau had a substantially increased risk of progressing to mild cognitive impairment compared with those negative for both. This shows these PET markers can identify high-risk individuals, but it does not test any treatment or prevention.

Study details

How this study scored 76/100
How this study's score is builtJournal tier 10 of 10; Journal's citation record 4 of 4; Study design 0 of 12; Strength of evidence 1 of 5; Peer-review validation 10 of 10; How recent 3 of 5; Sample size 3 of 4; Effect reported 3 of 3; Studied in people 3 of 3; Randomized / blinded 0 of 2; Times cited 6 of 7; Citations per year 5 of 5; Impact for its field and year 6 of 6; Cited by studies here 4 of 6; Still being cited 4 of 4; Senior author's track record 4 of 4; Institution's track record 3 of 3; Multicenter collaboration 3 of 3; Indexed in PubMed 2 of 2; Free to read 2 of 2. Total 76 of 100.76 of 100 points earned24 not earned

Published in a top-tier journal. Scored zero for study design and randomized / blinded because the record does not state it.

ComponentPointsWhy
Journal tier 10 / 10 Tier 1 — top-tier general journal (Nature medicine)
Journal's citation record 4 / 4 Nature Medicine: journal h-index 763 (OpenAlex, 2026-10-29)
Study design 0 / 12 No study design recorded — scores zero, not guessed (not stated in the record — scored 0)
Strength of evidence 1 / 5 Rated “low” in our summary
Peer-review validation 10 / 10 Peer-reviewed. Published as an article in a named peer-reviewed journal.
How recent 3 / 5 2022 — within 6 year(s) of the newest study here
Sample size 3 / 4 1,325 participants
Effect reported 3 / 3 Effect reported with a statistic (interval, p-value, ratio or similar)
Studied in people 3 / 3 Studied in people (participant count stated)
Randomized / blinded 0 / 2 No randomization or blinding stated — scores zero (not stated in the record — scored 0)
Times cited 6 / 7 Cited 497 times (OpenAlex, 2026-10-10)
Citations per year 5 / 5 82.8 citations a year over 6 year(s) since 2022
Impact for its field and year 6 / 6 Cited 57.3× the average for papers of its field and year (OpenAlex FWCI)
Cited by studies here 4 / 6 Cited by 53 other studies in this library
Still being cited 4 / 4 Cited 408 times in 2024–2026 (2026 still in progress; OpenAlex)
Senior author's track record 4 / 4 Last-listed author Oskar Hansson: h-index 148 (OpenAlex, whole career)
Institution's track record 3 / 3 Harvard University: institution h-index 3,235 (OpenAlex)
Multicenter collaboration 3 / 3 OpenAlex lists 17 institution(s) in 4 countries
Indexed in PubMed 2 / 2 Indexed in PubMed (PMID 36357681)
Free to read 2 / 2 Free to read
Total 76 / 100 —

What each of these 20 components measures, and what this score is not →

Read the original

Full text: free to read — OpenAlex lists this copy as free to read: the link above (checked 6 Feb 1020).

Studies in the library that share something with this one. The line above each title says what.

Studies this one cites

Referenced by this study and also in the alzhub library, so you can read them here. Showing 12 of 42.

Later studies that cite this one

53 studies in the alzhub library list this one in their references. Showing the 8 highest-scoring.

Related studies in Mild cognitive impairment from nearby years

Also tagged “phosphorylated”

732 studies in the library carry the topic tag “phosphorylated”; these are this study's neighbours in a fixed, alphabetical-by-hash tour of them, not the closest in content. All 732 tagged studies.

Studies sharing this one's topic tags

Similar studies

More on Mild cognitive impairment

See all studies in Mild cognitive impairment →